Pharmaceutical analysis and standardization of gimantan parenteral dosage form

The objective of this investigation was to develop methods for the pharmaceutical analysis of a parenteral dosage form of gimantan, a new anti-Parkinson’s drug. The physicochemical properties of gimantan solution for injection have been investigated. Methods for the determination of the impurity con...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical chemistry journal Vol. 45; no. 8; pp. 499 - 502
Main Authors Sergeeva, M. S., Grushevskaya, L. N., Pyatin, B. M., Avdyunina, N. I., Gaevaya, L. M., Klumova, V. S., Dudenkova, M. E., Alekseev, K. V., Litvin, E. A.
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.11.2011
Springer
Subjects
Analysis
Antiparkinsonian agents
Chromatography
Medicine
Organic Chemistry
Pharmaceutical industry
Pharmacology/Toxicology
Pharmacy
standardization
gimantan
parenteral dosage form
gas chromatography
thin-layer chromatography
pharmaceutical analysis
Online AccessGet full text

Cover

More Information
Summary:The objective of this investigation was to develop methods for the pharmaceutical analysis of a parenteral dosage form of gimantan, a new anti-Parkinson’s drug. The physicochemical properties of gimantan solution for injection have been investigated. Methods for the determination of the impurity content and the quantitative drug assay were developed based on thin-layer chromatography (TLC) and gas chromatography (GC), respectively. The drug was identified using TLC and GC simultaneously with the purity evaluation and quantitative determination of gimantan. The stability during storage has been studied. The quality standards for gimantan parenteral dosage form have been developed.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-011-0664-1